Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant

NCT00186667 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00186667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00186667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 1999
Completion date
September 30, 2005
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blood and marrow transplant (bmt), graft vs host disease